162 related articles for article (PubMed ID: 10687138)
1. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells.
Ribas A; Butterfield LH; Hu B; Dissette VB; Chen AY; Koh A; Amarnani SN; Glaspy JA; McBride WH; Economou JS
J Immunother; 2000 Jan; 23(1):59-66. PubMed ID: 10687138
[TBL] [Abstract][Full Text] [Related]
2. Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor.
Broder H; Anderson A; Odesa SK; Kremen TJ; Liau LM
Neurosurg Focus; 2000 Dec; 9(6):e6. PubMed ID: 16817689
[TBL] [Abstract][Full Text] [Related]
3. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.
Butterfield LH; Jilani SM; Chakraborty NG; Bui LA; Ribas A; Dissette VB; Lau R; Gamradt SC; Glaspy JA; McBride WH; Mukherji B; Economou JS
J Immunol; 1998 Nov; 161(10):5607-13. PubMed ID: 9820539
[TBL] [Abstract][Full Text] [Related]
4. MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor.
Broder H; Anderson A; Kremen TJ; Odesa SK; Liau LM
J Neurooncol; 2003; 64(1-2):21-30. PubMed ID: 12952283
[TBL] [Abstract][Full Text] [Related]
5. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells.
Liao YP; Wang CC; Butterfield LH; Economou JS; Ribas A; Meng WS; Iwamoto KS; McBride WH
J Immunol; 2004 Aug; 173(4):2462-9. PubMed ID: 15294960
[TBL] [Abstract][Full Text] [Related]
6. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.
Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ
J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
[TBL] [Abstract][Full Text] [Related]
8. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
[TBL] [Abstract][Full Text] [Related]
10. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.
Kim CJ; Prevette T; Cormier J; Overwijk W; Roden M; Restifo NP; Rosenberg SA; Marincola FM
J Immunother; 1997 Jul; 20(4):276-86. PubMed ID: 9220317
[TBL] [Abstract][Full Text] [Related]
12. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.
Ribas A; Butterfield LH; Hu B; Dissette VB; Meng WS; Koh A; Andrews KJ; Lee M; Amar SN; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Apr; 60(8):2218-24. PubMed ID: 10786687
[TBL] [Abstract][Full Text] [Related]
13. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma.
Philip R; Alters SE; Brunette E; Ashton J; Gadea J; Yau J; Lebkowski J; Philip M
J Immunother; 2000 Jan; 23(1):168-76. PubMed ID: 10687150
[TBL] [Abstract][Full Text] [Related]
15. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1.
Riemann H; Takao J; Shellman YG; Hines WA; Edwards CK; Franzusoff A; Norris DA; Fujita M
Exp Dermatol; 2007 Oct; 16(10):814-22. PubMed ID: 17845213
[TBL] [Abstract][Full Text] [Related]
16. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
17. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
[TBL] [Abstract][Full Text] [Related]
18. Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution.
Abdel-Wahab Z; Kalady MF; Emani S; Onaitis MW; Abdel-Wahab OI; Cisco R; Wheless L; Cheng TY; Tyler DS; Pruitt SK
Cell Immunol; 2003 Aug; 224(2):86-97. PubMed ID: 14609574
[TBL] [Abstract][Full Text] [Related]
19. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
[TBL] [Abstract][Full Text] [Related]
20. Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells.
Ribas A; Butterfield LH; McBride WH; Dissette VB; Koh A; Vollmer CM; Hu B; Chen AY; Glaspy JA; Economou JS
Cancer Gene Ther; 1999; 6(6):523-36. PubMed ID: 10608349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
